Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
Huabin Hu(Sun Yat-sen University), Yanhong Deng(Sun Yat-sen University), Xiaoyu Xie(Sun Yat-sen University), Cailu Shen(Sun Yat-sen University), Jiayu Ling(Sun Yat-sen University), Yue Cai(Sun Yat-sen University), Xuehu Xu(Third Affiliated Hospital of Guangzhou Medical University), Jianxia Li(The Affiliated Yongchuan Hospital of Chongqing Medical University), Jianwei Zhang(Capital Medical University), Weiwei Li, Chao Wang(McLean Hospital), Yan Huang(Shanghai Pulmonary Hospital), Zehua Wu(Shanghai Jiao Tong University)
Cited by 12
Related Papers
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
|Clinical Cancer Research|2018|456
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
|Journal of Clinical Oncology|2019|410
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial
|Journal of Clinical Oncology|2016|409
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
|Nature|2017|402